The Clinical Biochemistry Group aims to develop and improve diagnostic tools for a better and earlier detection of the diseases and also providing a precise tracking of the disease evolution. We have two main focal points in our research: 1) The massive sample and data process and analysis, aiming to a personalized medicine through big data analysis helped by artificial intelligence based on the massive number of results generated and controlled by our clinical laboratories (15 million tests per year). 2) The finding of new biomarkers using advanced technology as mass spectrometry or high throughput DNA and RNA analysis (Rare diseases, Parkinson, prostate cancer, hepatitis, COVID). We have designed advanced methods, now used in routine clinical practice, to adjust the dose of anticancer drugs, or biomarkers that help to diagnose cancer, kidney diseases, or rare diseases, and we are helping the personalized medicine to adjust reference values more precisely to each individual.
Group Leader
Francisco Rodríguez Frias
Principal Investigator (PI)
Rosanna Paciucci
Researchers
Roser Ferrer Costa, Joan López Hellin, Jose Antonio Arranz Amo, Clara Carnicer Cáceres, Imma Comas Reixach, Laura Conesa Milian, Maria Francesca Cortese, Wendy den Elzen, Rosanna Paciucci, Pilar Reimundo Díaz-Fierro, Rosa López Martínez, Jaume Vima Bofarull,.
PhD Students
Albert Blanco Grau, Luz Maria Cruz Carlos, Marina Giralt Arnáiz , Clara Ramirez Serra, Andrea Arias García, Laura Castellote Bellés, Pablo Gabriel Medina, Yolanda Villena Ortiz, Cristina Cea Arestín, Noelia Diaz Troyano, Luisa Martínez Sánchez, Raquel Barquin del Pino, Laura Castillo Ribelles, Selene Garcia Garcia, Beatriz Pacin Ruiz, Marta Vila Salvador, Emily Toscano Guerra, Alba Estela Garcia
31
PUBLICATIONS
51.6%
%Q1
210
IMPACT FACTOR
6.77
AVERAGE IMPACT FACTOR
SELECTED ARTICLES
Herance JR, Martín-Saladich Q, Velásquez MA, Hernandez C, Aparicio C, Ramirez-Serra C, Ferrer R, Giralt-Arnaiz M, González-Ballester MÁ, Pericàs JM, Castell-Conesa J, Aguadé-Bruix S, Simó R
Identification of Myocardial Insulin Resistance by Using Liver Tests: A Simple Approach for Clinical Practice.
Int J Mol Sci . 2022 Aug 7;23(15):8783
DOI: doi: 10.3390/ijms23158783
IF: 6.208
Martinez-Sanchez L, Gabriel-Medina P, Villena-Ortiz Y, García-Fernández AE, Blanco-Grau A, Cobbaert CM, Bravo-Nieto D, Garriga-Edo S, Sanz-Gea C, Gonzalez-Silva G, López-Hellín J, Ferrer-Costa R, Casis E, Rodríguez-Frías F, den Elzen WPJ.
Harmonization of indirect reference intervals calculation by the Bhattacharya method
Clin Chem Lab Med. 2022 Nov 17;61(2):266-274
DOI: doi: 10.1515/cclm-2022-0439
IF: 3.694
Díaz-Troyano N, Gabriel-Medina P, Weber S, Klammer M, Barquín-DelPino R, Castillo-Ribelles L, Esteban A, Hernández-González M, Ferrer-Costa R, Pumarola T, Rodríguez-Frías F
Soluble Angiotensin-Converting Enzyme 2 as a Prognostic Biomarker for Disease Progression in Patients Infected with SARS-CoV-2
Diagnostics (Basel). 2022 Apr 1;12(4):886.
DOI: doi: 10.3390/diagnostics12040886
IF: 3.992
Navarro-Romero A, Fernandez-Gonzalez I, Riera J, Montpeyo M, Albert-Bayo M, Lopez-Royo T, Castillo-Sanchez P, Carnicer-Caceres C, Arranz-Amo JA, Castillo-Ribelles L, Pradas E, Casas J, Vila M, Martinez-Vicente M.
Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone-mediated-autophagy deficiency, and alpha-synuclein pathology
NPJ Parkinsons Dis. 2022 Oct 6;8(1):126.
DOI: doi: 10.1038/s41531-022-00397-6
IF: 9.304
Recovery of serum testosterone levels is an accurate predictor of survival from COVID-19 in male patients. Toscano-Guerra E, Martínez-Gallo M, Arrese-Muñoz I, Giné A, Díaz-Troyano N, Gabriel-Medina P, Riveiro-Barciela M, Labrador-Horrillo M, Martinez-Valle F, Montalvá AS, Hernández-González M, Borrell RP, Rodríguez-Frias F, Ferrer R, Thomson TM, Paciucci R
Recovery of serum testosterone levels is an accurate predictor of survival from COVID-19 in male patients
BMC Med. 2022 Mar 29;20(1):129
DOI: doi: 10.1186/s12916-022-02345-w.
IF: 11.806
Detección temprana de recurrencia para una terapia personalizada en pacientes hormono-sensibles con cáncer de próstata metastásico.
Principal Investigator: Rosanna Paciucci Barzanti
Agency: Ministerio Economía, Industria y Competitividad
Funding: 108,900€
Period: 2019-2022
Role of Apolipoprotein A-Ib in the idiopathic nephrotic syndrome
Principal Investigator: Conxita Jacobs
Agency: La Marato de TV3
Funding: 199,966€
Period: 2021-2023
The interplay between ACE2 and AXL systems to predict COVID-19 disease severity and Outcomes
Principal Investigator: M.J. Soler Romeo
Agency: La Marató de TV3
Funding: 399,065€
Period: 2021-2023
RED NACIONAL DE LABORATORIOS DE FUNCION RENAL. Medida estandarizada del filtrado glomerular utilizando Iohexol
Principal Investigator: Esteban Porrini
Agency: CONVOCATORIA PROYECTOS DE INVESTIGACIÓN DE MEDICINA PERSONALIZADA. ISCIII MCIN
Funding: 1,337,976€
Period: 2022-2024
Exphlora: Cribado poblacional bioquímico y genético de hiperoxaluria primaria en España
Principal Investigator: Gema Ariceta
Agency: Alnylam Pharmaceuticals
Funding: 20,000€
Period: 2021-2023
eCOREs
